Cboe CA - Delayed Quote CAD

Eli Lilly and Company (LLY.NE)

Compare
29.78
+0.40
+(1.36%)
At close: January 10 at 3:58:40 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
40,863,300.00
34,124,100.00
28,541,400.00
28,318,400.00
24,539,800.00
Cost of Revenue
7,802,500.00
7,082,200.00
6,629,800.00
7,312,800.00
5,483,300.00
Gross Profit
33,060,800.00
27,041,900.00
21,911,600.00
21,005,600.00
19,056,500.00
Operating Expense
18,162,800.00
16,254,600.00
13,258,300.00
13,072,600.00
11,955,100.00
Operating Income
14,898,000.00
10,787,300.00
8,653,300.00
7,933,000.00
7,101,400.00
Net Non Operating Interest Income Expense
-518,700.00
-312,300.00
-268,800.00
-314,400.00
-326,600.00
Other Income Expense
-4,228,800.00
-3,920,400.00
-1,578,100.00
-1,463,100.00
455,100.00
Pretax Income
10,150,500.00
6,554,600.00
6,806,400.00
6,155,500.00
7,229,900.00
Tax Provision
1,780,600.00
1,314,200.00
561,600.00
573,800.00
1,036,200.00
Net Income Common Stockholders
8,369,900.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Diluted NI Available to Com Stockholders
8,369,900.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Basic EPS
0.25
0.16
0.18
0.16
0.18
Diluted EPS
0.25
0.16
0.18
0.16
0.18
Basic Average Shares
33,019,442.37
32,970,795.20
34,833,208.39
34,960,453.55
35,068,122.54
Diluted Average Shares
33,149,693.62
33,113,950.59
34,833,208.39
34,960,453.55
35,068,122.54
Total Expenses
25,965,300.00
23,336,800.00
19,888,100.00
20,385,400.00
17,438,400.00
Net Income from Continuing & Discontinued Operation
8,369,900.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Normalized Income
11,838,331.15
8,346,672.30
7,678,804.60
6,955,351.50
5,636,135.80
Interest Income
175,400.00
173,600.00
62,800.00
25,400.00
33,000.00
Interest Expense
694,100.00
485,900.00
331,600.00
339,800.00
359,600.00
Net Interest Income
-518,700.00
-312,300.00
-268,800.00
-314,400.00
-326,600.00
EBIT
10,844,600.00
7,040,500.00
7,138,000.00
6,495,300.00
7,589,500.00
EBITDA
12,514,100.00
8,567,800.00
8,660,500.00
8,042,900.00
8,913,400.00
Reconciled Cost of Revenue
7,802,500.00
7,082,200.00
6,629,800.00
7,312,800.00
5,483,300.00
Reconciled Depreciation
1,669,500.00
1,527,300.00
1,522,500.00
1,547,600.00
1,323,900.00
Net Income from Continuing Operation Net Minority Interest
8,369,900.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Total Unusual Items Excluding Goodwill
-4,206,300.00
-3,887,700.00
-1,563,800.00
-1,514,500.00
650,600.00
Total Unusual Items
-4,206,300.00
-3,887,700.00
-1,563,800.00
-1,514,500.00
650,600.00
Normalized EBITDA
16,720,400.00
12,455,500.00
10,224,300.00
9,557,400.00
8,262,800.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-737,868.85
-781,427.70
-129,795.40
-140,848.50
93,035.80
12/31/2020 - 9/19/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PFE.NE Pfizer Inc.
12.41
-1.12%
 
JNJ.NE JOHNSON & JOHNSON CDR (CAD HEDG
18.89
-1.72%
 
ABBV.NE AbbVie Inc.
25.23
-2.02%
 
JNJd.XC
 
600436.SS PIENTZEHUANG
204.40
-0.54%
 
MRK.VI Merck & Co., Inc.
97.70
+0.72%
 
NOVNEE.SW Novartis AG
91.37
-0.64%
 
COPNz.XC
 
ZEG.DE AstraZeneca PLC
131.25
+0.04%
 
RHO6.BE Roche Holding AG
35.60
0.00%